Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Dr. Michael Manns on a Possible Link Between Hepatitis C and Hepatocellular Carcinoma

April 20, 2016
By Michael Manns, MD
Publication
Video
HCC MonitorApril 2016
Volume 2
Issue 1

Michael Manns, MD, explains the possible link between hepatitis C and hepatocellular carcinoma.

Michael Manns, MD, director, Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover in Germany, explains the possible link between hepatitis C and hepatocellular carcinoma.

Manns says that patients who contracted hepatitis C or cirrhosis have showcased a greater risk of developing hepatocellular carcinoma (HCC), though drawing a direct link between the virus and HCC is difficult due to treatment of the virus depleting the potential control group. He concludes by pointing out that if a link is to be drawn between Hepatitis C and HCC, further testing must be done.

Articles in this issue

Dr. Michael Manns on a Possible Link Between Hepatitis C and Hepatocellular Carcinoma
Dr. Michael Manns on a Possible Link Between Hepatitis C and Hepatocellular Carcinoma
Dr. Anne Covey on Locoregional Therapy in Hepatocellular Carcinoma
Dr. Anne Covey on Locoregional Therapy in Hepatocellular Carcinoma
NCCN Guideline Calls Locoregional Therapy "Curative" for HCC
NCCN Guideline Calls Locoregional Therapy "Curative" for HCC
Genetically Modified T-Cell Therapy Cleared for Early Stage HCC Study
Genetically Modified T-Cell Therapy Cleared for Early Stage HCC Study
Neoadjuvant Sorafenib Induces Major Tumor Necrosis in HCC
Neoadjuvant Sorafenib Induces Major Tumor Necrosis in HCC
Committee Recommends Continuation of Phase III Tivantinib Study
Committee Recommends Continuation of Phase III Tivantinib Study
Liver Cancer Death Rates Defy Declining Trends
Liver Cancer Death Rates Defy Declining Trends
Moving Forward: Examining the Evolving Role of Embolization in HCC
Moving Forward: Examining the Evolving Role of Embolization in HCC
New Approaches to the Detection and Treatment of HCC With Portal Vein Thrombosis
New Approaches to the Detection and Treatment of HCC With Portal Vein Thrombosis
Novel Therapies on the Horizon in Hepatocellular Carcinoma
Novel Therapies on the Horizon in Hepatocellular Carcinoma

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
1 expert in this video
2 experts in this video
2 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

Tim Cortese
May 21st 2025
Article

Oral selinexor as maintenance therapy extended progression-free survival in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Read More


Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

Jordyn Sava;Susanne G. Warner, MD
October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen


Optimizing JAK Inhibitor Use for Hemoglobin and Platelet Regulation in Myelofibrosis (Part 2)

Optimizing JAK Inhibitor Use for Hemoglobin and Platelet Regulation in Myelofibrosis (Part 2)

Targeted Oncology Staff
May 19th 2025
Article

In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

Read More


MR-LINAC Provides Greater Precision  With Adaptive Radiation Across Cancers

MR-LINAC Provides Greater Precision With Adaptive Radiation Across Cancers

Morgan Bayer
May 17th 2025
Article

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Read More


Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Tony Berberabe, MPH
May 16th 2025
Article

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.

Read More


Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer

Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer

Chris Ryan
May 15th 2025
Article

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.

Read More

Related Content

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer

Tim Cortese
May 21st 2025
Article

Oral selinexor as maintenance therapy extended progression-free survival in patients with TP53 wild-type advanced or recurrent endometrial cancer.

Read More


Tailoring Treatments to Better Outcomes in Liver Cancer

Tailoring Treatments to Better Outcomes in Liver Cancer

Jordyn Sava;Susanne G. Warner, MD
October 13th 2023
Podcast

In season 4, episode 16 of Targeted Talks, Susanne G. Warner, MD,discusses the importance of tailoring treatments for patients with liver cancer, taking into account the staging of the cancer.

Listen


Optimizing JAK Inhibitor Use for Hemoglobin and Platelet Regulation in Myelofibrosis (Part 2)

Optimizing JAK Inhibitor Use for Hemoglobin and Platelet Regulation in Myelofibrosis (Part 2)

Targeted Oncology Staff
May 19th 2025
Article

In part 2, experts discuss optimizing the use of JAK inhibitors for patients with myelofibrosis.

Read More


MR-LINAC Provides Greater Precision  With Adaptive Radiation Across Cancers

MR-LINAC Provides Greater Precision With Adaptive Radiation Across Cancers

Morgan Bayer
May 17th 2025
Article

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Read More


Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Experts Will Explore Targetable Resistance Approaches During Lung Cancer Conference

Tony Berberabe, MPH
May 16th 2025
Article

For patients with EGFR-mutated NSCLC, treatment options in the frontline include osimertinib monotherapy, amivantamab with lazertinib, and osimertinib combined with platinum-doublet chemotherapy.

Read More


Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer

Novel ADC Generates Responses in Difficult-to-Treat Ovarian Cancer

Chris Ryan
May 15th 2025
Article

In the phase 2/3 REFRαME-O1 trial, luveltamab tazevibulin showed encouraging responses in patients with ovarian cancer with low to medium FRα expression.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.